| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C19H17N3O2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
BRD-6929 is a potent, selective, brain-penetrant inhibitor of the class I histone deacetylases HDAC1 and HDAC2, with IC50 values of 1 nM and 8 nM, respectively, and it binds HDAC1 and HDAC2 with high affinity (Ki of 0.2 nM and 1.5 nM, respectively). It can be used in mood-related behavioral model research[3]. It is supplied as an off-white to gray solid (C19H17N3O2S, MW 351.42) at 99.01% purity.
Physical & Chemical Properties
| CAS Number | 849234-64-6 |
|---|---|
| Molecular Formula | C19H17N3O2S |
| Molecular Weight | 351.42 g/mol |
| Purity | 99.01% |
| Appearance | Solid |
| Color | Off-white to gray |
| SMILES | O=C(NC1=CC(C2=CC=CS2)=CC=C1N)C3=CC=C(NC(C)=O)C=C3 |
| Target | HDAC1, HDAC2, HDAC3, HIV-1 |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics; Anti-infection |
| Solubility | In Vitro: DMSO: 25 mg/mL (71.14 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1][3]
|
HDAC1 1 nM (IC50) |
HDAC2 8 nM (IC50) |
HDAC3 458 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Li-Huei Tsai, et al. Inhibition of hdac2 to promote memory. patent/US20120101147
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 25 mg/mL (71.14 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (5.92 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
In vitro IC50 values of BRD-6929 for HDAC1-9 are determined with recombinant human HDAC enzymes and HDAC class-specific substrates. With BRD-6929 and substrate incubated for 180 min (HDAC1-3) to control for HDAC1-3 inhibition, BRD-6929 has IC50s of 0.001 μM, 0.008 μM, 0.458 μM and >30 μM against HDAC1, HDAC2, HDAC3 and HDAC4-9, respectively[1]. For in vitro binding affinity (Ki) and kinetics (half-life ‘T1/2′ in minutes), HDAC 1, 2 and 3 are incubated with BRD-6929 (10 μM); the Ki values are <0.2 nM, 1.5 nM, and 270 nM for HDAC 1, 2 and 3, respectively. Half-lives (T1/2) are >2400 mins for HDAC 1, >4800 mins for HDAC 2, and 1200 mins for HDAC 3[1]. BRD-6929 (1 and 10 uM) leaves overall cell number unchanged, with neither an increase nor a decrease, in brain region specific primary cultures. In addition, H4K12 acetylation increases with BRD-6929 (10 uM) in brain region specific primary cultures (striatum)[1]. In primary neuronal cell cultures, BRD-6929 (1-10 uM; 6 hours) significantly increases H2B acetylation. In cultured neurons, BRD-6929 (1-20 uM; 24 hours) induces dose-dependent acetylation of H4K12ac with an EC50 of 7.2 μM[1]. Against latent HIV-1, BRD-6929 potentiates the efficacy of gnidimacrin (a PKC Agonist)[3].
In Vivo
After a single intraperitoneal injection at 45 mg/kg, BRD-6929 gives plasma values of 17.7 μM (Cmax), 7.2 hours (T1/2), and 25.6 μM/L*hr (AUC). In brain, it gives 0.83 μM (Cmax), 6.4 hours (T1/2), and 3.9 μM/L*hr (AUC)[1]. Given intraperitoneally at 45 mg/kg for 10 days, BRD-6929 acts as a deacetylase inhibitor in mouse brain, significantly increasing acetylation in each brain region by 1.5- to 2.0-fold relative to vehicle. In adult male C57BL/6J mice, western blotting reveals significantly raised acetylation from BRD-6929 on histone H2B (tetra-acetylated), H3K9 and H4K12 after the 10th daily treatment, in cortex, ventral striatum and hippocampus[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
The Probiotic Parabacteroides johnsonii Ameliorates Metabolic Disorders Through Promoting BCAAs to BSCFAs Conversion. Adv Sci (Weinh) 2025 Aug 7:e02624. PMID: 40772426
DNTTIP1 drives leukaemogenesis through MiDAC-mediated epigenetic silencing of BMF. Clin Transl Med 2026 Feb;16(2):e70603. PMID: 41603084
Butyrate rescues chlorpyrifos-induced social deficits through inhibition of class I histone deacetylases. bioRxiv 2025 Oct 20:2025.10.19.683261. PMID: 41280077
